文献速递肝病消化道肿瘤与早癌

美国肝硬化与肝细胞癌基于病因及种族的年死亡率变化趋势

Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.
PubMed 文献 · Hepatology · 2019-02-11

该研究利用美国人口普查与国家死亡数据库,分析2007至2016年美国20岁以上成人肝硬化与肝细胞癌的年龄标化死亡率。结果显示肝硬化相关死亡率从19.77/10万升至23.67/10万,肝细胞癌相关死亡率从3.48/10万升至4.41/10万;丙型肝炎肝硬化死亡率在2014至2016年显著下降,而酒精性肝病、非酒精性脂肪性肝病及肝细胞癌死亡率持续上升,少数族裔负担更高。

要点

  • 2007至2016年美国肝硬化相关死亡率年均增长2.3%,肝细胞癌相关死亡率年均增长2.0%。
  • 丙型肝炎肝硬化死亡率在2014至2016年年均下降6.5%,而酒精性肝病(年均增4.5%)和非酒精性脂肪性肝病(年均增15.4%)肝硬化死亡率上升。
  • 少数族裔人群肝细胞癌相关死亡率负担更高。

核心结论

  • 2007至2016年美国肝硬化与肝细胞癌相关死亡率均上升,但丙型肝炎肝硬化死亡率在直接抗病毒药物时代(2014至2016年)显著下降。
  • 酒精性肝病/非酒精性脂肪性肝病肝硬化及肝细胞癌死亡率持续上升,乙型肝炎肝硬化死亡率下降,少数族裔终末期肝病相关死亡率负担不成比例地更高。

研究设计与样本

  • 基于美国人口普查和国家死亡数据库的人群研究,纳入2007至2016年美国20岁及以上成人,计算年龄标化的病因特异性肝硬化与肝细胞癌死亡率,并用连接点分析估计年度百分比变化(APC)。

主要发现

  • 肝硬化相关年龄标化死亡率从2007年的19.77/10万升至2016年的23.67/10万,年均增长2.3%(95%CI 2.0-2.7)。
  • 丙型肝炎肝硬化死亡率APC从2007至2014年的每年增长2.9%转为2014至2016年的每年下降6.5%。
  • 酒精性肝病肝硬化APC为4.5%,非酒精性脂肪性肝病肝硬化APC为15.4%,乙型肝炎肝硬化平均APC为-1.1%。
  • 肝细胞癌相关死亡率从2007年的3.48/10万升至2016年的4.41/10万,年均增长2.0%(95%CI 1.3-2.6);肝细胞癌的病因特异性死亡率模式与肝硬化相关死亡率基本一致。
  • 少数族裔人群肝细胞癌相关死亡率负担更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With recent improvements in the treatment of end-stage liver disease (ESLD), a better understanding of the burden of cirrhosis and hepatocellular carcinoma (HCC) is needed in the United States. A population-based study using the US Census and national mortality database was performed. We identified the age-standardized etiology-specific mortality rates for cirrhosis and HCC among US adults ages 20 years or older from 2007 to 2016. We determined temporal mortality rate patterns by joinpoint analysis with estimates of annual percentage change (APC). Age-standardized cirrhosis-related mortality rates increased from 19.77/100,000 persons in 2007 to 23.67 in 2016 with an annual increase of 2.3% (95% confidence interval [CI] 2.0-2.7). The APC in mortality rates for hepatitis C virus (HCV)-cirrhosis shifted from a 2.9% increase per year during 2007 to 2014 to a 6.5% decline per year during 2014 to 2016. Meanwhile, mortality for cirrhosis from alcoholic liver disease (ALD, APC 4.5%) and NAFLD (APC 15.4%) increased over the same period, whereas mortality for hepatitis B virus (HBV)-cirrhosis decreased with an average APC of -1.1%. HCC-related mortality increased from 3.48/100,000 persons in 2007 to 4.41 in 2016 at an annual rate of 2.0% (95% CI 1.3-2.6). Etiology-specific mortality rates of HCC were largely consistent with cirrhosis-related mortality. Minority populations had a higher burden of HCC-related mortality. Conclusion: Cirrhosis-related and HCC-related mortality rates increased between 2007 and 2016 in the United States. However, mortality rates in HCV-cirrhosis demonstrated a significant decline from 2014 to 2016, during the direct-acting antiviral era. Mortality rates for ALD/NAFLD-cirrhosis and HCC have continued to increase, whereas HBV-cirrhosis-related mortality declined during the 10-year period. Importantly, minorities had a disproportionately higher burden of ESLD-related mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kim D, Li AA, Perumpail BJ, et al. Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology. 2019. PMID: 30014489. doi:10.1002/hep.30161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。